Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness
| Autor: | Efe Eworuke, Michael D. Blum, Elnara Fazio-Eynullayeva, Jennifer G. Lyons, Sengwee Toh, Amanda Carruth, Elizabeth C. Dee, Catherine A. Panozzo, Michael D. Nguyen, Sarah K. Dutcher |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Filgrastim Epidemiology Patient characteristics Healthcare Common Procedure Coding System 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Internal medicine Claims data Hematologic Agents Product Surveillance Postmarketing Medicine Humans Pharmacology (medical) 030212 general & internal medicine Biosimilar Pharmaceuticals Safety studies business.industry Pharmacoepidemiology Biosimilar Infliximab United States Reference product Antirheumatic Agents business medicine.drug |
| Zdroj: | Pharmacoepidemiology and drug safetyREFERENCES. 29(7) |
| ISSN: | 1099-1557 |
| Popis: | PURPOSE To describe utilization of filgrastim and infliximab, the first two products with biosimilars approved in the United States. METHODS We identified use of filgrastim (reference, tbo-filgrastim, and filgrastim-sndz) and infliximab (reference, infliximab-dyyb, and infliximab-abda) in the Sentinel Distributed Database using Healthcare Common Procedure Coding System (HCPCS) codes and National Drug Codes (NDCs) from January 2015 to August 2018. We calculated the proportion of use by code type and assessed uptake over time. We compared baseline patient characteristics and treatment indications. Among patients with >1 exposure episode, we characterized gaps between episodes. RESULTS Use was identified primarily via HCPCS codes (filgrastim: 86.4%-97.7%; infliximab: 87.8%-100%) although some was identified via NDCs (filgrastim: 2.2%-13.5%; infliximab |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text